| 3.61 0.18 (5.25%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.27  |
1-year : | 4.99 |
| Resists | First : | 3.66 |
Second : | 4.27 |
| Pivot price | 2.79 |
|||
| Supports | First : | 2.62 |
Second : | 1.98 |
| MAs | MA(5) : | 3.27 |
MA(20) : | 2.61 |
| MA(100) : | 2.42 |
MA(250) : | 2.11 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 92.1 |
D(3) : | 91.7  |
| RSI | RSI(14): 82.7 |
|||
| 52-week | High : | 3.66 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IMMX ] has closed above the upper band by 3.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 143.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.68 | 3.68 - 3.69 |
| Low: | 3.22 - 3.23 | 3.23 - 3.24 |
| Close: | 3.58 - 3.61 | 3.61 - 3.63 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Tue, 14 Oct 2025
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Investing News Network
Tue, 14 Oct 2025
Immix Biopharma, Inc. to Present at Guggenheim Healthcare Innovation Conference on November 11, 2025 - Quiver Quantitative
Mon, 06 Oct 2025
Immix Biopharma, Inc. to Present NXC-201 Abstract at ASH 67th Annual Meeting | IMMX Stock News - Quiver Quantitative
Mon, 06 Oct 2025
NXC-201 Abstract: Immix Biopharma to Present at ASH 67th Annual Meeting in Orlando Dec 6-9, 2025 - Stock Titan
Wed, 01 Oct 2025
Clinical-Stage Cell Therapy Developer ImmixBio to Showcase AL Amyloidosis Pipeline at Major Healthcare Conference - Stock Titan
Wed, 01 Oct 2025
Immix Biopharma, Inc. to Host Investor Meetings at 37th Annual Piper Sandler Healthcare Conference - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 35.7 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 522 (K) |
| Shares Short P.Month | 369 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.9 % |
| Return on Equity (ttm) | -162.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4.69 |
| PEG Ratio | 0 |
| Price to Book value | 22.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|